Alkem Laboratories Limited will conduct its 52nd Annual General Meeting (AGM) on Thursday, August 27, 2026, at 11.00 a.m. IST via video conferencing (VC) or other audio-visual means (OAVM). The meeting will be held in compliance with the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with relevant Ministry of Corporate Affairs circulars. The company will send the Annual Report for the financial year 2025-26 and the Notice of AGM electronically to members whose email IDs are registered with the company or depository participants.

The Board of Directors, at its meeting held on May 28, 2026, recommended a final dividend of ₹10 per equity share of ₹2 each for the financial year ended March 31, 2026. This dividend is subject to the approval of members at the ensuing AGM. If approved, the payment will be made on and from Tuesday, September 1, 2026. The company noted that dividend paid on or after April 1, 2026, is taxable in the hands of members, and tax deducted at source (TDS) will be applicable as per the provisions of the Income-Tax Act, 2025.

Alkem Laboratories is providing a remote e-voting facility to all members to cast their votes on resolutions set forth in the Notice of AGM. Members have the option to vote using the remote e-voting facility or e-voting during the AGM. The Annual Report and Notice of AGM will be available on the company's website, the websites of BSE Limited and National Stock Exchange of India Limited, and the CDSL website.

Members are required to register their email addresses to receive the Annual Report and future communications. The registration process can be completed via a specific link provided by the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited. For queries related to registration, members may contact the designated helpdesk or the company's registrar.

Key Meeting Details

Alkem Laboratories has received favourable Orders-in-Appeal from the Commissioner of Income Tax, Appeal – 47, Mumbai (CIT(A)) for Assessment Years (AYs) 2018-19 to 2022-23. The orders, received on 30th June, 2026, pertain to the deletion of disallowances made under Section 80-IE of the Income-tax Act, 1961, involving a tax amount of ₹660.77 Crores. The company confirmed that there is no material impact on its financial, operational, or other activities.

Background of the Tax Dispute

The dispute originated when the Assessing Officer disallowed part of the deduction claimed under Section 80-IE of the Income-tax Act, 1961, in re-assessment orders passed under Section 143(3)/144 read with Section 147 of the Act for AYs 2018-19 to 2022-23. Alkem Laboratories subsequently filed appeals before the CIT(A), which have now been decided in the company's favour. The CIT(A) has passed orders deleting the said disallowances across all five assessment years in question.

Key Details of the Orders-in-Appeal

The following table summarises the key details of the favourable orders as disclosed by the company:

Company's Disclosure and Compliance

Alkem Laboratories confirmed that the orders have no material impact on the financial, operational, or other activities of the company. The disclosure was made in compliance with Clause 20 of Para A of Part A of Schedule III of the SEBI Listing Regulations. The information has also been made available on the company's official website at www.alkemlabs.com . The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, on 1st July, 2026.